Drug Profile

Hydrocodone controlled-release - Currax Pharmaceuticals

Alternative Names: AFI-001; Hydrocodone bitartrate; Hydrocodone ER; Hydrocodone extended release; Zohydro ER; ZX 007; ZX-002

Latest Information Update: 27 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daravita
Developer Zogenix
Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
Mechanism of Action Opioid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Marketed Pain

Most Recent Events

23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
07 Mar 2022 Zogenix has been acquired by UCB
30 Apr 2019 Currax Pharmaceuticals acquired all the assets of Pernix Therapeutics ,

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com